CHICAGO – At the American Society of Clinical Oncology annual meeting this week, researchers presented new data on treatments for non-small cell lung cancer patients with ALK rearrangements and MET alterations in their tumors.
The data suggest that the precision oncology drug market in NSCLC will get even more crowded in the coming months and years, and patient populations will be further dissected according to molecular tumor characteristics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
